Barclays
NRIX icon

Barclays’s Nurix Therapeutics NRIX Stock Holding History

Barclays’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.36M Buy
183,852
+161,370
+718% +$4.02M ﹤0.01% 2120
2026
Q2 		$545K Sell
22,482
-1,698
-7% -$28.9K ﹤0.01% 3162
2026
Q1 		$375K Sell
24,180
-232,504
-91% -$3.86M ﹤0.01% 3347
2025
Q4 		$4.87M Buy
256,684
+11,589
+5% +$166K ﹤0.01% 2240
2025
Q3 		$2.26M Sell
245,095
-9,775
-4% -$102K ﹤0.01% 2803
2025
Q2 		$2.9M Buy
254,870
+110,095
+76% +$1.19M ﹤0.01% 2557
2025
Q1 		$1.72M Sell
144,775
-4,561
-3% -$76.3K ﹤0.01% 2734
2024
Q4 		$2.81M Buy
149,336
+20,992
+16% +$481K ﹤0.01% 2644
2024
Q3 		$2.88M Buy
128,344
+56,190
+78% +$1.27M ﹤0.01% 2547
2024
Q2 		$1.51M Buy
72,154
+24,639
+52% +$384K ﹤0.01% 2338
2024
Q1 		$698K Sell
47,515
-21,224
-31% -$228K ﹤0.01% 3374
2023
Q4 		$709K Buy
68,739
+1,272
+2% +$8.72K ﹤0.01% 3669
2023
Q3 		$530K Sell
67,467
-1,524
-2% -$13.9K ﹤0.01% 2770
2023
Q2 		$689K Sell
68,991
-3,156
-4% -$32.2K ﹤0.01% 2556
2023
Q1 		$641K Sell
72,147
-27,510
-28% -$287K ﹤0.01% 3085
2022
Q4 		$1.09M Buy
99,657
+15,166
+18% +$183K ﹤0.01% 2715
2022
Q3 		$1.1M Buy
84,491
+81,760
+2,994% +$1.29M ﹤0.01% 2163
2022
Q2 		$34K Sell
2,731
-2,448
-47% -$27.7K ﹤0.01% 4195
2022
Q1 		$72K Buy
+5,179
New +$91.9K ﹤0.01% 3940

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.6B AUM 38.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays's NRIX Position: Q3 2026 in Review

Barclays increased its Nurix Therapeutics (NRIX) stake by 718% in Q3 2026, buying an estimated $4.02M and bringing the position to 183,852 shares worth $4.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2120.

Barclays first reported a position in NRIX in Q1 2022 and has held it in 19 quarters since. The position peaked at $4.87M in Q4 2025. 91 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Barclays held 183,852 shares of Nurix Therapeutics worth $4.36M as of Q3 2026.
  • Barclays bought 161,370 Nurix Therapeutics shares in Q3 2026, an estimated $4.02M.
  • Nurix Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2120 holding.
  • Barclays first reported a position in Nurix Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Nurix Therapeutics position peaked at $4.87M in Q4 2025.
  • 91 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.